Aamal Company and its fully owned subsidiary, Ebn Sina Medical – announced today signing a distribution agreement with Turkish Company CinnaGen Ilaç, an established firm which started operating in Turkey in 2016. The deal involves importing several biotech drugs to Qatar used for medical treatment of multiple sclerosis, rheumatoid arthritis, cancer, and blood diseases. 

Sheikh Mohamed Bin Faisal Al Thani – Vice Chairman and Managing Director of Aamal Company– commented: “We are very pleased to announce this agreement with CinnaGen Ilaç, which reflects Aamal’s persistence on exploring new international markets and creating cooperative relationships with companies that go in line with the quality standards of Aamal has set for its products. We are positive that this deal will support Ebn Sina organic growth, which include being alert to the market demands and adopt a proactive approach partnering with leading institutions to provide the local market with the best and latest pharmaceutical products to meet the increasing market needs”.